Inhalant pins change hands, and domestic brands rise! 13 products break through the new medical insurance

Recently, the inhalant market has made waves again, and 4 companies of 2 inhalants have been approved
on the same day as the production of imitation 4 categories.
In addition, 13 inhalants were included in the list of drugs that were adjusted to the 2022 National Medical Insurance Catalogue through formal review
.
Intranet data show that in the first half of 2022, the sales of terminal inhalants in public hospitals in key provinces and cities fell by nearly 10%
year-on-year.
Inhaled sevoflurane ascended to the throne of "pin crown", and 3 major products advanced to the top 10
.
Since 2018, a total of 43 inhalants (170 acceptance numbers) have been submitted for trial, of which more than 20 products have not been approved by domestic enterprises, involving Chia Tai Tianqing Pharmaceutical Group, Sichuan Puruite Pharmaceutical, Jiangsu Hengrui Pharmaceutical, Jiangsu Kangyuan Pharmaceutical, etc
.

 

2 inhalers 4 enterprises were approved on the same day, and 13 products broke through the new medical insurance

 

　　

On September 19, 2022, the drug approval certificate documents are to be released

 

A few days ago, the official website of the State Food and Drug Administration showed that Hebei Renhe Yikang Pharmaceutical, Shanxi Youshengmeite Pharmaceutical, Jiangsu Wu Traditional Chinese Medicine Group Suzhou Pharmaceutical Factory for inhalation of acetyl cysteine solution, Shandong Dongwei Pharmaceutical Terbutaline sulfate atomization inhalation solution were approved on the same day as imitation Class 4 production, which is regarded as over-evaluation
.
Among them, no enterprise has been approved for acetylcysteine solution for inhalation before this
.
Since the beginning of this year, 9 inhalers (29 product regulations) have been approved for listing
.

 

　

The 2022 National Medical Insurance Catalogue adjusts inhalers that pass the formal examination

 

In addition, the high-profile 2022 National Medical Insurance Catalogue adjustment through the formal review of the list of drugs officially announced, 13 inhalers shortlisted, of which 11 are exclusive products
.
8 products such as chloromethacholine for inhalation and ambroxol hydrochloride spray are products outside the catalog, and 5 products in the catalogue, such as propylcaterol hydrochloride powder aerosol and Budigev inhalation aerosol
.

 

Chia Tai Tianqing Pharmaceutical Group's inhaled chloromethacholine was approved for listing in March this year.
In diagnostics?? Tube? Road? Reactive chloromethylcholine excitation test, ?? Clinically significant asthma symptoms in the form of progress? Patients and 5 years of age and older who can cooperate well? Pediatric patients
.
From the perspective of innovation, on the one hand, a breakthrough? Methylcholine? The technical barriers of fungal preparations that are easy to deliquesh and difficult to pack are realized? Essence of Methylcholine? Change? production; On the other hand the product is China? Approved? In?? The excitation agent of the tube excitation test, the quality control of the API is more stringent than the original research, and the quality of the preparation and the quality of the original research are more stringent.
Yes
.

 

Luoxin Pharmaceutical's ambroxol hydrochloride spray is suitable? 2-6 years old? Children's sputum is viscous and sputum discharge is difficult, the product is a national class 2.
4 new drug, owned? Ambroxol hydrochloride? Cavity spray and preparation? Law and other invention patents, which belong to the 2018 national "heavy? New drug creation "science and technology heavy? Special achievements
.
At the same time, is the domestic only?? Fund? Children's College? Expectorant? Take the spray, the dosage of the drug is precise, the efficacy is exact, Drug safety, feeding? Convenient and carry-on
.
It is understood that ambroxol hydrochloride spray is the first spray product of Luoxin Pharmaceutical, which occupies an important position in the company's respiratory disease drugs, which is reflected in the technical advantages in this field and the layout in the children's drug market, which will have a positive impact on
the company.

 

Inhaler "pin crown" changed owners! 3 products have made it into the TOP10

 

Intranet data show that in 2022, the terminal inhalant market of public hospitals in key provinces and cities will decline by nearly 10%
year-on-year due to factors such as collection and procurement.
From the perspective of quarterly sales trends, the second quarter fell the most
.

 

　　

In the first half of 2022, the terminal inhalant products of key provincial and municipal public hospitals are TOP10

 

The market concentration of inhalants is high, and the total market share of the top 10 products accounts for more than 70%.

Inhaled sevoflurane ascended to the throne of "pin crown", and sales in 2021 and the first half of 2022 maintained steady growth, 18.
68% and 6.
86% respectively, of which Shanghai Hengrui Pharmaceutical had the largest
market share.
At present, 7 enterprises with inhaled sevoflurane have production approvals, and 4 companies such as Sichuan Baili Pharmaceutical and Fujian Haixi United Pharmaceutical are under review
.

 

In addition, levalbutamol hydrochloride nebulized inhalation solution, inhalation of beclomethasone propionate suspension and budigofu inhaled aerosol rose to the top ten with strong growth rates, with a year-on-year increase of more than 100%.

 

　

In the first half of 2022, the brand pattern of sevoflurane for terminal inhalation in public hospitals in key provinces and cities

 

As of now, a total of 5 products have been included in the national collection, and the suspensions for inhalation and terbutaline sulfate atomized inhalation solutions are TOP10 products
.

 

It is worth mentioning that with the efforts of domestic pharmaceutical companies, the market share of original research drugs has declined rapidly, and the effect of domestic substitution is obvious
.
Among them, GlaxoSmithKline's inhalation salbutamol sulfate solution fell the most, from more than 90% in 2020 to less than 10%
in the first half of 2022.

 

　　

In the first half of 2022, the terminal inhalant brands of key provincial and municipal public hospitals are TOP10

 

Among the top 10 brands, Shanghai Hengrui Pharmaceutical's inhaled sevoflurane, AstraZeneca's budesonide formoterol inhalation powder mist (II.
), and Zambang's acetyl cysteine solution for inhalation ranked in the top three
.

 

Heavy new products are coming, Zhengda Tianqing, Priet.
.
.
Sprint to the first in China

 

　　

Since 2018, there have been no approved inhalers in China that are under trial

 

Since 2018, a total of 43 inhalants (170 acceptance numbers) have been submitted for trial, and from the perspective of treatment subcategories, drugs for obstructive tracheal diseases have dominated the mainstream
.

 

In addition, more than 20 inhalants such as dexmetomidine hydrochloride nasal spray, afortol tartrate atomization inhalation solution, indacaterol maleate powder inhaler, sodium cromoglycate inhalation solution and other domestic inhalers have not been approved, involving Sichuan Priit Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group, Jiangsu Hengrui Pharmaceutical, Jiangsu Kangyuan Pharmaceutical and other enterprises, who will take the lead? Intranet will continue to pay attention
.

 

Source: State Food and Drug Administration's official website, Intranet database, etc

 

Note: The competition pattern database of chemical drug terminals in public hospitals in key provinces and cities of Minetnet is based on the chemical drug procurement data of nearly 700 sample provinces and cities in 20+ provinces and cities, and continuously monitors the sample provinces and cities of all categories of chemical drugs; The above sales are calculated
based on the average retail price of the product at the terminal.
If there is any omission, please correct it!